GB201803892D0 - C-met binding agents - Google Patents

C-met binding agents

Info

Publication number
GB201803892D0
GB201803892D0 GBGB1803892.7A GB201803892A GB201803892D0 GB 201803892 D0 GB201803892 D0 GB 201803892D0 GB 201803892 A GB201803892 A GB 201803892A GB 201803892 D0 GB201803892 D0 GB 201803892D0
Authority
GB
United Kingdom
Prior art keywords
binding agents
met binding
met
agents
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1803892.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lockbody Therapeutics Ltd
Original Assignee
Ultrahuman Six Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultrahuman Six Ltd filed Critical Ultrahuman Six Ltd
Priority to GBGB1803892.7A priority Critical patent/GB201803892D0/en
Publication of GB201803892D0 publication Critical patent/GB201803892D0/en
Priority to GBGB1812487.5A priority patent/GB201812487D0/en
Priority to GBGB1816841.9A priority patent/GB201816841D0/en
Priority to US16/980,015 priority patent/US11673960B2/en
Priority to CN201980017468.2A priority patent/CN111819200B/zh
Priority to CN202410570377.4A priority patent/CN118459588A/zh
Priority to JP2020543219A priority patent/JP7458567B2/ja
Priority to CA3092526A priority patent/CA3092526A1/en
Priority to PCT/EP2019/056178 priority patent/WO2019175186A1/en
Priority to AU2019233511A priority patent/AU2019233511B2/en
Priority to EP19711070.3A priority patent/EP3765509A1/en
Priority to US18/304,598 priority patent/US12415861B2/en
Priority to US19/304,080 priority patent/US20260042850A1/en
Priority to AU2026202717A priority patent/AU2026202717A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1803892.7A 2018-03-12 2018-03-12 C-met binding agents Ceased GB201803892D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1803892.7A GB201803892D0 (en) 2018-03-12 2018-03-12 C-met binding agents
GBGB1812487.5A GB201812487D0 (en) 2018-03-12 2018-07-31 C-Met binding agents
GBGB1816841.9A GB201816841D0 (en) 2018-03-12 2018-10-16 C-met binding agents
EP19711070.3A EP3765509A1 (en) 2018-03-12 2019-03-12 Anti c-met antibodies
JP2020543219A JP7458567B2 (ja) 2018-03-12 2019-03-12 C-met結合剤
CN201980017468.2A CN111819200B (zh) 2018-03-12 2019-03-12 抗c-met抗体
CN202410570377.4A CN118459588A (zh) 2018-03-12 2019-03-12 抗c-met抗体
US16/980,015 US11673960B2 (en) 2018-03-12 2019-03-12 Anti C-MET antibodies
CA3092526A CA3092526A1 (en) 2018-03-12 2019-03-12 Anti c-met antibodies
PCT/EP2019/056178 WO2019175186A1 (en) 2018-03-12 2019-03-12 Anti c-met antibodies
AU2019233511A AU2019233511B2 (en) 2018-03-12 2019-03-12 Anti C-MET antibodies
US18/304,598 US12415861B2 (en) 2018-03-12 2023-04-21 Anti C-MET antibodies
US19/304,080 US20260042850A1 (en) 2018-03-12 2025-08-19 Anti c-met antibodies
AU2026202717A AU2026202717A1 (en) 2018-03-12 2026-04-10 Anti c-met antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1803892.7A GB201803892D0 (en) 2018-03-12 2018-03-12 C-met binding agents

Publications (1)

Publication Number Publication Date
GB201803892D0 true GB201803892D0 (en) 2018-04-25

Family

ID=61972884

Family Applications (3)

Application Number Title Priority Date Filing Date
GBGB1803892.7A Ceased GB201803892D0 (en) 2018-03-12 2018-03-12 C-met binding agents
GBGB1812487.5A Ceased GB201812487D0 (en) 2018-03-12 2018-07-31 C-Met binding agents
GBGB1816841.9A Ceased GB201816841D0 (en) 2018-03-12 2018-10-16 C-met binding agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
GBGB1812487.5A Ceased GB201812487D0 (en) 2018-03-12 2018-07-31 C-Met binding agents
GBGB1816841.9A Ceased GB201816841D0 (en) 2018-03-12 2018-10-16 C-met binding agents

Country Status (8)

Country Link
US (3) US11673960B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765509A1 (cg-RX-API-DMAC7.html)
JP (1) JP7458567B2 (cg-RX-API-DMAC7.html)
CN (2) CN111819200B (cg-RX-API-DMAC7.html)
AU (2) AU2019233511B2 (cg-RX-API-DMAC7.html)
CA (1) CA3092526A1 (cg-RX-API-DMAC7.html)
GB (3) GB201803892D0 (cg-RX-API-DMAC7.html)
WO (1) WO2019175186A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
JP7510518B2 (ja) * 2020-09-01 2024-07-03 レメゲン シーオー.,エルティーディー. 抗c-Met抗体薬物複合体及びその応用
EP4232087A4 (en) * 2020-10-21 2024-10-09 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS
AR125473A1 (es) * 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
CN115724970B (zh) * 2022-07-27 2023-10-20 生工生物工程(上海)股份有限公司 一种特异性结合e-cad多肽的结合蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2383295T3 (en) * 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US20140112911A9 (en) 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
BRPI1015234A2 (en) * 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
HK1201855A1 (en) * 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CN104321322A (zh) * 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
CN106458916A (zh) * 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents

Also Published As

Publication number Publication date
WO2019175186A1 (en) 2019-09-19
CN111819200A (zh) 2020-10-23
US12415861B2 (en) 2025-09-16
JP2021516537A (ja) 2021-07-08
CN111819200B (zh) 2024-05-28
CN118459588A (zh) 2024-08-09
GB201812487D0 (en) 2018-09-12
AU2019233511A1 (en) 2020-10-15
US20210009694A1 (en) 2021-01-14
US20260042850A1 (en) 2026-02-12
US20230295311A1 (en) 2023-09-21
EP3765509A1 (en) 2021-01-20
GB201816841D0 (en) 2018-11-28
JP7458567B2 (ja) 2024-04-01
AU2019233511B2 (en) 2026-01-15
US11673960B2 (en) 2023-06-13
AU2026202717A1 (en) 2026-04-30
CA3092526A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
IL272643A (en) Binders
GB201802201D0 (en) Binding agents
IL277343A (en) CD47 binding factors
GB201814169D0 (en) Blockchain autonoumous agents
GB202105206D0 (en) Compounds
GB201816841D0 (en) C-met binding agents
IL268288A (en) Binders
SG11202008246VA (en) Pd1 binding agents
IL277131A (en) PD1 binding factors
EP3954914C0 (en) SLIDING COMPONENTS
LT3587708T (lt) Rišimo aparatas
PL3848537T3 (pl) Wiązarka
PL3848292T3 (pl) Wiązarka
GB201804094D0 (en) ERBB3 Binding agents
PL3848533T3 (pl) Wiązarka
IL276914A (en) CSF1R binding factors
GB201803571D0 (en) Component
GB201801634D0 (en) #
SG11202105131TA (en) Polyamide composition
GB201807046D0 (en) Combination
GB201813568D0 (en) Component
GB201801130D0 (en) Compounds
GB201808570D0 (en) Binding agents
GB201802595D0 (en) Binding agents
GB201713296D0 (en) Binding agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)